Organon & Co. (NYSE:OGN) Price Target Raised to $8.00

Organon & Co. (NYSE:OGN) had its target price upped by Barclays from $7.50 to $8.00 in a research note issued to investors on Tuesday morning,Benzinga reports. Barclays currently has an underweight rating on the stock.

A number of other equities research analysts also recently issued reports on OGN. Zacks Research downgraded Organon & Co. from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Wall Street Zen lowered Organon & Co. from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Morgan Stanley lowered their price target on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 11th. Piper Sandler downgraded Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target for the company. in a research report on Monday, October 27th. Finally, JPMorgan Chase & Co. cut their price objective on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a report on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and five have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $8.50.

Organon & Co. Stock Performance

Shares of OGN stock opened at $7.22 on Tuesday. The firm’s 50 day moving average is $7.98 and its 200 day moving average is $8.48. The stock has a market capitalization of $1.88 billion, a P/E ratio of 10.17, a PEG ratio of 0.68 and a beta of 0.58. Organon & Co. has a 12 month low of $6.18 and a 12 month high of $16.08. The company has a current ratio of 1.82, a quick ratio of 1.20 and a debt-to-equity ratio of 11.47.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). The business had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.52 billion. Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The company’s revenue was down 5.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.90 EPS. On average, sell-side analysts anticipate that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 12th. Investors of record on Monday, February 23rd will be issued a dividend of $0.02 per share. The ex-dividend date of this dividend is Monday, February 23rd. This represents a $0.08 annualized dividend and a dividend yield of 1.1%. Organon & Co.’s dividend payout ratio (DPR) is currently 11.27%.

Institutional Trading of Organon & Co.

Several institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC increased its holdings in shares of Organon & Co. by 105.2% in the fourth quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock worth $61,282,000 after buying an additional 4,394,814 shares during the period. Vanguard Group Inc. grew its position in Organon & Co. by 11.3% during the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock worth $383,715,000 after acquiring an additional 3,650,860 shares during the last quarter. Norges Bank purchased a new position in Organon & Co. in the 2nd quarter worth approximately $19,778,000. UBS Group AG increased its stake in Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock worth $30,795,000 after purchasing an additional 1,527,492 shares during the period. Finally, Private Management Group Inc. lifted its position in Organon & Co. by 38.3% in the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after purchasing an additional 1,204,979 shares during the last quarter. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.